av-001
Peptideexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 16, 2020 (NCT04737486)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase TIE-2ACTIVATOR
TEK activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07234890 | Phase 2 | Dec 1, 2025 | University of Western Ontario |
| NCT05123755 | Phase 2 | Nov 30, 2021 | Vasomune Therapeutics, Inc. |
| NCT04737486 | Phase 1 | Dec 16, 2020 | Medpace, Inc., Vasomune Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vasomune Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2020 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2020 |
| University of Western Ontario | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1